Q-omics provides the consensus-scored CBX3P5 profile across patient tissues and cancer cell-line models. CBX3P5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CBX3P5 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, CBX3P5 RNA expression shows 10,486 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where CBX3P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX3P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX3P5 survival associations across molecular data types. CBX3P5 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX3P5 RNA expression–survival associations across cancer types. High CBX3P5 expression shows unfavorable associations in ACC, PAAD, LUSC and STAD, but favorable associations in LIHC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CBX3P5 RNA expression.
This table summarizes CBX3P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CBX3P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX3P5 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LUSC and BRCA. The HNSC box plot shows higher CBX3P5 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .001).
This table shows molecular features associated with CBX3P5 in patient tissues and cancer cell lines. In patient samples, CBX3P5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
